^SAMPLE = GSM854870!Sample_title = SMZL#17_F-CTRL!Sample_geo_accession = GSM854870!Sample_status = Public on Jan 01 2014!Sample_submission_date = Dec 29 2011!Sample_last_update_date = Jan 01 2014!Sample_type = genomic!Sample_channel_count = 2!Sample_source_name_ch1 = SMZL#17!Sample_organism_ch1 = Homo sapiens!Sample_taxid_ch1 = 9606!Sample_characteristics_ch1 = gender: female!Sample_characteristics_ch1 = tissue: spleen tumor!Sample_characteristics_ch1 = disease: splenic marginal zone lymphoma!Sample_treatment_protocol_ch1 = Spleen tumour cell suspensions were collected before any specific chemotherapy or immunotherapy.!Sample_growth_protocol_ch1 = Spleen tumour cell suspensions were collected from patients that had undergone therapeutic splenectomy between 1999-2009 and were stored in the Biological Resource Centre of the Hospices Civils de Lyon, France.!Sample_molecule_ch1 = genomic DNA!Sample_extract_protocol_ch1 = Total high quality genomic DNA was isolated according to the manufacturerâs instructions (Qiagen, Germantown, MD, USA) from frozen tumour spleen samples containing more than 60% of malignant B cells based on flow cytometry immunophenotyping or from control samples.!Sample_label_ch1 = Alexa-5!Sample_label_protocol_ch1 = Digested DNA products were labeled using random priming with either Alexa-5-dUTP or Alexa-3-dUTP using the Bioprime Total Genomic Labeling System (Invitrogen, California, USA) according to the manufacturerâs instructions.!Sample_source_name_ch2 = F-CTRL!Sample_organism_ch2 = Homo sapiens!Sample_taxid_ch2 = 9606!Sample_characteristics_ch2 = gender: female!Sample_characteristics_ch2 = tissue: blood!Sample_characteristics_ch2 = disease: healthy!Sample_treatment_protocol_ch2 = Spleen tumour cell suspensions were collected before any specific chemotherapy or immunotherapy.!Sample_growth_protocol_ch2 = Spleen tumour cell suspensions were collected from patients that had undergone therapeutic splenectomy between 1999-2009 and were stored in the Biological Resource Centre of the Hospices Civils de Lyon, France.!Sample_molecule_ch2 = genomic DNA!Sample_extract_protocol_ch2 = Total high quality genomic DNA was isolated according to the manufacturerâs instructions (Qiagen, Germantown, MD, USA) from frozen tumour spleen samples containing more than 60% of malignant B cells based on flow cytometry immunophenotyping or from control samples.!Sample_label_ch2 = Alexa-3!Sample_label_protocol_ch2 = Digested DNA products were labeled using random priming with either Alexa-5-dUTP or Alexa-3-dUTP using the Bioprime Total Genomic Labeling System (Invitrogen, California, USA) according to the manufacturerâs instructions.!Sample_hyb_protocol = Each tumour samples (SMZL) were combined either with the female reference DNA or with the male reference DNA using a dye swap methodology to obtain a sex-matched and a sex-mismatch CGH profile. After denaturation, probes were pre-annealed with 50 Âµg of human Cot-1 DNA (Invitrogen, California, USA) and hybridization was performed at 65Â°C for 24 hours.!Sample_scan_protocol = The arrays were scanned on an Agilent G2565AA scanner.!Sample_description = Patient SMZL#17 versus female reference (dye-swap)!Sample_data_processing = Microarray images were analyzed using Agilent Feature Extraction Software (version 9.5.3.1) for background subtraction and normalization.!Sample_platform_id = GPL15068!Sample_contact_name = Laurent,,JALLADES!Sample_contact_email = laurent.jallades@chu-lyon.fr!Sample_contact_phone = 33(0)4 78 86 15 15!Sample_contact_fax = 33(0)4 78 86 33 40!Sample_contact_laboratory = Haematology!Sample_contact_institute = Hospices Civils de Lyon!Sample_contact_address = 165 Chemin du Grand Revoyet!Sample_contact_city = Pierre Benite!Sample_contact_zip/postal_code = 69495!Sample_contact_country = France!Sample_supplementary_file = ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM854nnn/GSM854870/suppl/GSM854870_252182510016_3.txt.gz!Sample_series_id = GSE34768!Sample_data_row_count = 45220#ID_REF = #VALUE = normalized log10 ratio Cy5/Cy3!sample_table_beginID_REF	VALUE1	7.359701772e-0032	0.000000000e+0003	-1.895357754e-0014	0.000000000e+0005	0.000000000e+0006	0.000000000e+0007	0.000000000e+0008	0.000000000e+0009	0.000000000e+00010	0.000000000e+00011	0.000000000e+00012	-2.028651220e-00213	9.654436997e-00214	1.601130956e-00115	1.526658931e-00116	-1.194286693e-00217	-4.286950360e-00218	5.394077497e-00219	2.423201915e-00320	-4.495011677e-002!sample_table_end